Smith & Nephew (LON:SN) Lowered to “Buy” Rating by Citigroup

Citigroup lowered shares of Smith & Nephew (LON:SN) to a buy rating in a research report report published on Friday morning, Marketbeat.com reports.

Several other equities analysts also recently issued reports on SN. Royal Bank Of Canada restated a “sector perform” rating and issued a GBX 1,350 price objective on shares of Smith & Nephew in a research note on Monday, June 29th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a GBX 1,400 target price on shares of Smith & Nephew in a research report on Thursday, June 11th. UBS Group reissued a “neutral” rating and issued a GBX 1,300 target price on shares of Smith & Nephew in a report on Tuesday, May 5th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,760 target price on shares of Smith & Nephew in a research report on Thursday, May 21st. Finally, Berenberg Bank restated a “hold” rating and set a GBX 13 price target on shares of Smith & Nephew in a research note on Friday, May 1st. Three equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Smith & Nephew currently has an average rating of “Hold” and a consensus price target of GBX 1,382.62.

Smith & Nephew Price Performance

Shares of LON:SN opened at GBX 1,140 on Friday. The stock’s 50 day moving average is GBX 1,125.75 and its two-hundred day moving average is GBX 1,204.47. The company has a debt-to-equity ratio of 62.90, a current ratio of 2.57 and a quick ratio of 0.84. The firm has a market cap of £12.50 billion, a price-to-earnings ratio of 41.04, a P/E/G ratio of 0.46 and a beta of 0.68.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.